Rena Kaminsky

Special Counsel
Full contact info

Experience

Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179

February 14, 2024

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Rama Padmanabhan
Partner, San Diego
Rajdeep Roger Bains
Associate, San Diego
Jason Savich
Partner, San Francisco
Lila Hope
Partner, Palo Alto
Michael Klein
Partner, New York
Michelle Garcia Schulman
Partner, Reston
Matthew S. Scarano
Associate, San Diego
Jameson Davis
Associate, Palo Alto
Kaiting Yang
Associate, Hong Kong
Ross Eberly
Partner, Los Angeles Santa Monica
Jeffrey J. Tolin
Partner, New York
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Robert Eisenbach
Of Counsel, San Francisco
Rena Kaminsky
Special Counsel, Palo Alto
Olya Antle
Associate, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Yoni Horn
Associate, Los Angeles Santa Monica
Patrick Sharma
Associate, Los Angeles Santa Monica
Lunga Su
Associate, Shanghai
Yiying Wang
Associate, Shanghai

Related Practices & Industries

Gracell Biotechnologies Agrees to Acquisition by AstraZeneca for up to $1.2 Billion

December 26, 2023

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Rowook Park
Partner, San Diego
Izzy Lubarsky
Partner, New York
Brittany K. Wightman
Associate, San Diego
Rajdeep Roger Bains
Associate, San Diego
Melissa Meza
Associate, San Diego
Will Cai
Partner, Hong Kong
Patrick Loofbourrow
Partner, Singapore
Jie Zhang
Partner, Hong Kong
Hilda Li
Associate, Hong Kong
Samantha Zhang
Associate, Singapore
Alessandra Murata
Partner, Palo Alto
Charity Williams
Partner, San Diego
Xander Lee
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Megan Browdie
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Ross Eberly
Partner, Los Angeles Santa Monica
Lei Shen
Partner, Chicago
Natasha Leskovsek
Of Counsel, Washington, DC
Rena Kaminsky
Special Counsel, Palo Alto
Stella Sarma
Special Counsel, Brussels
Christine Graham
Special Counsel, London
Andrew Epstein
Special Counsel, Seattle
Dillon Martinson
Special Counsel, Washington, DC
Ajay Athavale
Associate, San Francisco
Amanda Griggs
Associate, New York
Sara Kim
Associate, Los Angeles Downtown
Patrick Sharma
Associate, Los Angeles Santa Monica
Allison Kutner
Associate, New York
Eileen Leman
Associate, Los Angeles Downtown
Daniel Lac
Associate, San Diego
Sarah Oliai
Associate, Washington, DC

Related Practices & Industries

SystImmune Announces Global Strategic Collaboration With Bristol Myers Squibb

December 11, 2023

Cooley advised SystImmune, a clinical-stage biopharmaceutical company, on its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune’s BL-B01D1.

Read more

Related contacts

Kate Hillier
Partner, Seattle
Lila Hope
Partner, Palo Alto
Chen Chen
Partner, Boston
Aaron Pomeroy
Partner, Colorado
Todd Gluth
Partner, San Diego
Rick Jantz
Associate, Los Angeles Santa Monica
Jonathan Kaufman
Associate, Palo Alto
Zack Gong
Associate, Shanghai
Rena Kaminsky
Special Counsel, Palo Alto
Freddy Yip
Associate, Hong Kong
David D. Suh
Associate, Palo Alto
David Burns
Special Counsel, Washington, DC
Rubin Waranch
Associate, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Daniel Millard
Associate, London
Zhijing Yu
Associate, Singapore
Rachel Thorn
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Christopher Kimball
Partner, Washington, DC
Dillon Martinson
Special Counsel, Washington, DC
Annie Froehlich
Partner, Washington, DC

Related Practices & Industries

Senti Biosciences Sells Certain Assets to Celadon Partners

August 14, 2023

Cooley advised Senti Biosciences, a biotechnology company, on its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners.

Read more

Related contacts

Maureen Nagle
Special Counsel, Washington, DC
Luke X. Blackett
Associate, San Francisco
Chrystal Cantrelle
Associate, Washington, DC
Rena Kaminsky
Special Counsel, Palo Alto
Freddy Yip
Associate, Hong Kong
Peter Crain
Special Counsel, Reston
Alanna B Zuchelli
Associate, Reston
Ross Eberly
Partner, Los Angeles Santa Monica
Marya Postner
Partner, Palo Alto
Helen Luu
Associate, Palo Alto
Aric Wu
Partner, New York
Rachel Thorn
Partner, New York
Barbara Mirza
Partner, Los Angeles Santa Monica
Christopher Kimball
Partner, Washington, DC
Dee Bansal
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Stacey A. Bradford
Special Counsel, Washington, DC
J. Brian Stalter
Special Counsel, New York
Annie Froehlich
Partner, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Zack Gong
Associate, Shanghai
Nicholas Balenger
Associate, Reston
Rachel Boyce
Associate, San Francisco
Ajay Athavale
Associate, San Francisco
Sarah Oliai
Associate, Washington, DC
Leina Verrier
Associate, Los Angeles Santa Monica
Patricia Myers
Paralegal Specialist, Colorado

Related Practices & Industries

Neurocrine Biosciences Enters Collaboration Agreement with Sosei Heptares

November 23, 2021

We represented Neurocrine Biosciences in its strategic collaboration and licensing agreement with Sosei Heptares to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment of schizophrenia, dementia and other neuropsychiatric disorders.

Under the terms of the agreement, Neurocrine Biosciences gains development and commercialization rights to a broad portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei Heptares in development for the treatment of major neurological disorders. Sosei Heptares received a total of $100 million in upfront cash and is eligible to receive up to approximately $1.5 billion related to the successful progression of licensed candidates through to regulatory approval. Sosei Heptares is also eligible to receive up to $1.1 billion upon achieving certain global sales milestones of any products developed under the partnership and is eligible to receive tiered royalties ranging from high single digit to mid-teen percentage on future net sales.

Lawyers Kay Chandler and Rena Kaminsky led the Cooley team advising Neurocrine.

 

Related contacts

Rena Kaminsky
Special Counsel, Palo Alto

Related Practices & Industries

View more

Memberships & affiliations

American Bar Association